Malaysia Airlines named world's fastest-growing airline brand, AirAsia also soars in global ranking
The national carrier's brand value surged by 209 per cent to USD$607 million, securing the 45th spot globally—a remarkable comeback to the rankings after a decade. Malaysia Airlines attributed this growth to fleet renewal, strategic route realignments, digital transformation, and international expansion initiatives.
In addition, the airline achieved a Brand Strength Index (BSI) score of 78.2/100 and an AA+ brand strength rating. Brand Finance noted that the airline's strong domestic loyalty and trust, driven by high levels of consideration and word-of-mouth recognition in its home market, were key to its resurgence.
Meanwhile, airasia climbed two positions to rank 24th globally, with its brand value rising by 66 per cent to USD1.9 billion. The low-cost carrier's growth was bolstered by strong financial performance, high passenger load factors, and strategic expansions, including new routes to Chongqing, China, and Nairobi, Kenya. It also improved frequencies on popular routes during peak travel seasons.
Airasia now ranks as the world's 11th strongest airline brand, with a BSI score of 84.2/100 and a AAA- brand strength rating.
Alex Haigh, Managing Director Asia-Pacific at Brand Finance, praised the achievements of both airlines.
'Malaysia Airlines' resurgence as the fastest-growing airline brand globally underscores the success of its strategic transformation. Meanwhile, airasia continues to demonstrate resilience and financial agility, capitalising on strategic network expansion initiatives.
'Together, these two Malaysian carriers highlight the strength and dynamic potential of the nation's aviation industry on the global stage,' he said.
Brand Finance's Airports 25 2025 sub-ranking also recognised Malaysia Airports, which saw its brand value increase by 83 per cent to USD$184 million, ranking as the seventh strongest airport brand globally with a BSI score of 80.3/100 and a AAA- rating.
Globally, the combined brand value of the top 50 airlines rose by 29 per cent to USD$132.6 billion, reflecting the continued recovery of the aviation sector. Delta retained its position as the world's most valuable airline brand, valued at USD$14.9 billion, while Southwest Airlines ranked as the strongest airline brand with a BSI score of 91.1/100.
This year's report highlights the resilience and dynamism of the global aviation industry, with Malaysia Airlines and airasia making significant contributions to the nation's presence on the global stage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Hanwha Life Completes Acquisition of U.S.-Based Velocity Clearing, LLC, Becoming the First Korean Insurer to Signal a Bold Expansion into North American Capital Markets
Entering the U.S. securities industry as the first Korean insurance companyDelivers 25% CAGR in Revenue Over the Past Three Years… Proves Business Growth and Stability in the U.S. Stock MarketStrengthening U.S. market competitiveness through global financial synergy with the U.S. affiliate and Hanwha AI Center SEOUL, South Korea and NEW YORK, July 30, 2025 /PRNewswire/ — Hanwha Life, South Korea's first life insurance company, has officially completed the acquisition of a 75% stake in U.S.-based global financial services firm Velocity Clearing, LLC on July 30 (EST). The majority of the stake acquired was owned by an affiliate of Cerberus Capital Management, L.P. The deal marks a bold strategic move into the North American capital markets—beyond Hanwha Life's traditional insurance business. With this transaction, Hanwha Life becomes the first Korean insurance company to acquire a U.S. securities firm, 'the center of the global capital markets.' The acquisition establishes a platform for Hanwha Life to enhance its profitability through a local U.S. financial company and provide high-quality global financial products to global clients. Velocity Clearing, LLC, a global financial services firm based in New York, manages the post trade service, including clearing and settlement. As of the end of 2024, the firm held approximately USD 1.2 billion in total assets, with a compound annual growth rate (CAGR) of 25% in revenue over the last three years (2022~2024). The net income is also increasing steadily, with continued profitability expected after the acquisition. Working closely with Velocity Clearing, LLC, under its existing leadership, the company aims to ensure early operational stability while building strategic synergies with its U.S. asset management affiliate, Hanwha Asset Management (USA) Ltd. and the Hanwha AI Center (HAC), located in San Francisco. This collaboration will combine financial expertise with the advanced AI capabilities to strengthen Hanwha Life's competitive edge in the U.S. market. Hanwha Life representative said, 'This transaction represents a significant step for Korean finance to establish a presence in the key financial center, the U.S. capital markets. Moving forward, we will continue to strengthen our global business by leveraging digital financial technologies and our global network to ensure sustainable, long-term growth.' Michael Logan, CEO of Velocity Clearing, stated, 'With Hanwha Life's global vision and support, we expect to accelerate our growth and unlock new opportunities together for our clients. We're excited about the powerful synergies ahead.' Brian Schaeffer, president of Velocity Clearing, said, 'This partnership with Hanwha Life is client driven, allowing Velocity Clearing to further accelerate its product and geographic expansion.' Lee Millstein, Chairman of Global Real Estate for Cerberus, stated, 'We're proud to have supported Velocity Clearing through an exciting period of growth, and Hanwha Life is well-positioned to build on that momentum in the company's next chapter.' About Hanwha LifeEstablished in 1946 as Korea's first life insurance company, Hanwha Life has over 78 years of experience and reported total consolidated assets of USD 108.9 billion (KRW 160.2 trillion) as of the end of 2024. While maintaining leadership in the insurance sector, Hanwha Life is accelerating its transformation into a global financial group through innovation and strategic overseas expansion. The company continues to expand its global financial ecosystem by pursuing regionally tailored strategies and strengthening its digital capabilities. By building strong global partnerships, Hanwha Life aims to become a trusted global financial brand that delivers comprehensive and sustainable financial solutions. About Velocity ClearingVelocity Clearing is a technology-driven, self-clearing broker/dealer providing execution services, clearing, and custody along with access to stock locate services, securities lending, competitive financing, and a firm-wide focus on world-class customer service. Velocity Clearing supports retail traders and institutional clients including brokers/dealers, hedge funds, family offices, and proprietary trading firms in the United States and across the globe. With a growing team of professionals in multiple locations throughout the United States and across the globe, Velocity has the right combination of resources and people to provide seamless and reliable service to clients. Velocity Clearing is registered with the SEC and a member of FINRA and SIPC. Hanwha LifeErin Jundef[email protected] Velocity ClearingRich Myers[email protected]
Malaysian Reserve
a day ago
- Malaysian Reserve
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034)
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics, and greater investment in research and development. Along with these, the launch of emerging therapies such as DATROWAY, PADCEV, BNT327/ PM8002, and others will fuel the TNBC market growth. LAS VEGAS, July 29, 2025 /PRNewswire/ — DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Triple-Negative Breast Cancer Market Report According to DelveInsight's analysis, the market size for triple-negative breast cancer was found to be USD 4.5 billion in the 7MM in 2024. The United States accounted for the highest market size of TNBC, approximately 69% of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. As per the estimates, among the current treatment options, KEYTRUDA (pembrolizumab) and chemotherapy held the largest TNBC treatment market share, generating approximately USD 2 billion in revenue in 2024 across the 7MM. In 2024, 7MM recorded approximately 104K new TNBC cases. With a projected CAGR of 0.7%, the number of cases is expected to gradually rise, leading to a higher disease burden by 2034. Leading triple-negative breast cancer companies developing emerging therapies, such as AstraZeneca, Daiichi Sankyo, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, and others, are developing new TNBC treatment drugs that can be available in the triple-negative breast cancer market in the coming years. The promising triple-negative breast cancer therapies in the pipeline include DATROWAY (Datopotamab Deruxtecan), PADCEV (Enfortumab vedotin), Tilarginine, BNT327/PM8002, IMFINZI (Durvalumab), and others. Discover the TNBC new treatment @ New Treatments for TNBC Triple-Negative Breast Cancer Market Dynamics The triple-negative breast cancer market dynamics are expected to change in the coming years. Combining chemotherapy, immunotherapy, and targeted therapies, such as TALZENNA and TRODELVY, offers enhanced disease control and expands treatment options for advanced-stage TNBC patients, while innovations in immune checkpoint inhibitors, therapeutic vaccines, and ongoing research into personalized approaches are transforming long-term management by boosting immune response, improving survival rates, and addressing the need for more effective, tailored solutions beyond first-line therapy As potential therapies are being investigated for the treatment of triple-negative breast cancer, it is safe to predict that the treatment space will significantly impact the triple-negative breast cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the triple-negative breast cancer market in the 7MM. However, several factors may impede the growth of the triple-negative breast cancer market. TNBC is the most difficult breast cancer subtype to manage due to its aggressive nature, lack of targeted treatment options, and high rates of chemotherapy resistance, which contribute to frequent relapse, reduced treatment efficacy, and limited long-term remission, even when diagnosed early; this underscores the urgent need for innovative, effective therapies that not only improve outcomes and prevent disease progression but also minimize the significant side effects of current aggressive treatments like chemotherapy and immunotherapy, which severely impact patient quality of life. Moreover, triple-negative breast cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the triple-negative breast cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the triple-negative breast cancer market growth. Triple-Negative Breast Cancer Treatment Market Triple-negative breast cancer lacks expression of hormone receptors and HER2, rendering it unresponsive to endocrine and HER2-targeted therapies. Consequently, systemic chemotherapy has long been the mainstay of treatment, especially in metastatic settings. Management typically starts with neoadjuvant or adjuvant chemotherapy, progressing to first-line treatments in advanced stages. If the disease advances or shows inadequate response, additional lines of therapy are introduced. Immunotherapies, particularly PD-1/PD-L1 inhibitors, are increasingly being utilized in metastatic TNBC to boost the body's immune defense against cancer cells. In early-stage TNBC, the PD-1 inhibitor KEYTRUDA (pembrolizumab) has become a standard part of treatment. It is administered with neoadjuvant chemotherapy and then continued as adjuvant monotherapy. In PD-L1-positive patients (CPS ≥10), it is also used alongside chemotherapy for locally recurrent or metastatic disease. Targeted therapies are making headway as well, particularly for patients with BRCA mutations. In such cases, PARP inhibitors like LYNPARZA (olaparib) and TALZENNA (talazoparib) target defective DNA repair pathways. TRODELVY (sacituzumab govitecan), an antibody-drug conjugate (ADC) targeting TROP-2, is approved for relapsed or treatment-resistant metastatic TNBC. Although TECENTRIQ (atezolizumab) was withdrawn from the U.S. market after failing confirmatory trials, it is still available in Europe and Japan. Taxane-based chemotherapy continues to be a cornerstone of TNBC treatment and is often combined with immune checkpoint inhibitors in PD-L1-positive cases. Platinum-based chemotherapy, though occasionally used, has shown mixed results due to concerns over toxicity and limited benefit. Despite therapeutic progress, TNBC remains a particularly aggressive subtype, underscoring the urgent need for continued innovation. Overall, current treatments frequently fall short of achieving lasting disease control, highlighting the pressing demand for novel therapies that can improve long-term outcomes and survival for TNBC patients. To know more about FDA-approved drugs for TNBC, visit @ Approved TNBC Treatment Triple-Negative Breast Cancer Pipeline Therapies and Key Companies Some of the drugs in the pipeline include DATROWAY [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], IMFINZI [(Durvalumab), AstraZeneca], PADCEV [(Enfortumab vedotin), Astellas Pharma and Pfizer], Tilarginine [(L-NMMA), Galera Therapeutics], and others. Datopotamab deruxtecan (Dato-DXd), also known as DATROWAY, is an experimental antibody-drug conjugate (ADC) being evaluated for the treatment of triple-negative breast cancer, both as a standalone therapy and in combination with IMFINZI (durvalumab). The therapy is aimed at high-risk TNBC patients, including those who are PD-L1-positive. Results from pivotal Phase III trials are expected in 2025, with more comprehensive findings anticipated by 2026, potentially influencing future treatment approaches for TNBC. Currently in Phase III development for TNBC, Dato-DXd is part of a global collaboration between AstraZeneca and Daiichi Sankyo, initiated in July 2020. Under this partnership, Daiichi Sankyo retains exclusive rights in Japan and oversees manufacturing and supply, while both companies are co-developing the drug across several cancer types globally. Tilarginine (L-NMMA), a broad nitric oxide synthase (NOS) inhibitor, is under Phase II investigation for metaplastic breast cancer (MpBC) in combination with alpelisib and nab-paclitaxel in HER2-negative metastatic or locally advanced settings. It is also being explored with a taxane in Phase II trials for patients with metastatic or locally advanced TNBC. In December 2024, Galera Therapeutics acquired Nova Pharmaceuticals. IMFINZI (durvalumab), an FDA-approved PD-L1 inhibitor developed by AstraZeneca for other cancers, works by blocking PD-L1 to enhance immune system recognition and destruction of tumor cells. It is currently undergoing Phase I/II studies in combination with paclitaxel and other novel therapies as a first-line option for metastatic TNBC (mTNBC), with key data expected by late 2025. Notably, the BEGONIA trial (October 2023) reported durable and significant tumor responses from the combination of datopotamab deruxtecan and IMFINZI when used as a first-line treatment for patients with mTNBC, along with a favorable safety profile. The anticipated launch of these emerging therapies are poised to transform the triple-negative breast cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the triple-negative breast cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about triple-negative breast cancer drugs in development @ Triple-Negative Breast Cancer Clinical Trials Recent Developments in the Triple-Negative Breast Cancer Market In May 2025, Gilead Sciences, Inc. reported that TRODELVY (sacituzumab govitecan-hziy) combined with KEYTRUDA (pembrolizumab) lowered the risk of disease progression or death by 35% (hazard ratio: 0.65) compared to the standard treatment of Keytruda plus chemotherapy as a first-line therapy for patients with PD-L1–positive (CPS ≥10) metastatic triple-negative breast cancer (TNBC). In May 2025, Gilead Sciences, Inc. reported positive topline results from the Phase 3 ASCENT-03 trial evaluating TRODELVY (sacituzumab govitecan-hziy). The study achieved its primary goal by showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not eligible for PD-1/PD-L1 inhibitors, either due to being PD-L1 negative or otherwise unsuitable for immunotherapy. In December 2024, Galera Therapeutics completed the acquisition of Nova Pharmaceuticals. Triple-Negative Breast Cancer Overview Triple-negative breast cancer is a particularly aggressive and diverse form of breast cancer that lacks expression of estrogen receptors (ER), progesterone receptors (PR), and HER2. It accounts for a substantial share of breast cancer cases and is associated with fast disease progression, high chances of recurrence, and unfavorable outcomes. TNBC tends to occur more frequently in younger women, individuals of African American descent, and those with BRCA1 gene mutations. The risk factors for TNBC are divided into two categories: non-modifiable factors, such as age, gender, genetic mutations, family history, and breast density, and modifiable ones, which include obesity, exposure to certain chemicals, and specific drug use. Due to its aggressive behavior and absence of hormone receptors, TNBC is particularly difficult to treat, highlighting the need for continuous research to enhance therapeutic approaches and patient survival. Diagnosis typically involves imaging tools like mammography, ultrasound, and MRI, followed by tissue sampling techniques including core needle biopsy, fine needle aspiration, or surgical biopsy. TNBC tumors are often high-grade and poorly differentiated, and the disease is staged using the TNM system, which evaluates tumor size, lymph node involvement, and the extent of metastasis. Triple-Negative Breast Cancer Epidemiology Segmentation The triple-negative breast cancer epidemiology section provides insights into the historical and current triple-negative breast cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The triple-negative breast cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Breast Cancer Total Incident Cases of TNBC Gene Mutation-specific Incident Cases of TNBC Stage-specific Incident Cases of TNBC Age-specific Incident Cases of TNBC Line-wise Treated Incident Cases of TNBC Triple-Negative Breast Cancer Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Triple-Negative Breast Cancer Market CAGR 4.7 % Triple-Negative Breast Cancer Market Size in 2024 USD 4.5 Billion Key Triple-Negative Breast Cancer Companies AstraZeneca, Daiichi Sankyo, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, Merck, Gilead Sciences, Roche, Genentech, and others Key Triple-Negative Breast Cancer Therapies DATROWAY (Datopotamab Deruxtecan), PADCEV (Enfortumab vedotin), Tilarginine, BNT327/PM8002, IMFINZI (Durvalumab), KEYTRUDA, TRODELVY, TALZENNA, LYNPARZA, TECENTRIQ, and others Scope of the Triple-Negative Breast Cancer Market Report Therapeutic Assessment: Triple-Negative Breast Cancer current marketed and emerging therapies Triple-Negative Breast Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging Triple-Negative Breast Cancer Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Triple-Negative Breast Cancer Market Access and Reimbursement Download the report to understand which factors are driving triple-negative breast cancer market trends @ Triple-Negative Breast Cancer Market Forecast Table of Contents 1 Key Insights 2 Report Introduction 3 TNBC Market Overview at a Glance 3.1 Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2020 3.2 Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2034 4 Executive Summary 5 Key Events 6 Disease Background and Overview 6.1 Introduction 6.2 Various Subtypes of Breast Cancer Based on Immunohistochemical Expression 6.3 TNBC Overview 6.3.1 Intrinsic Molecular Subtypes in TNBC 6.3.2 Characteristics of Tumor Microenvironment in TNBC 6.3.3 Potential Risk Factors 6.3.4 Clinical Presentation 6.3.5 Characterization of HER2-low Breast Cancers 6.4 Diagnosis 6.4.1 Staging 6.4.2 Grading 6.4.3 Clinical Prognostic Stage 6.4.4 Pathological Prognostic Stage 6.4.5 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer 6.4.6 Recommendations for HER2 Testing in Breast Cancer: American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline Update 6.4.7 Diagnostic Algorithm 6.5 Treatment and Management 6.5.1 NCCN Clinical Practice Guidelines in Oncology for Breast Cancer 6.5.2 ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Early Breast Cancer 6.5.3 ESMO Clinical Practice Guideline for the Diagnosis, Staging, and Treatment of Patients with Metastatic Breast Cancer 6.5.4 Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for Breast Cancer – 2022 Update 6.5.5 Treatment Algorithm 7 Epidemiology and Market Forecast Methodology 8 Epidemiology and Patient Population 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.2.1 Incident Cases of Breast Cancer 8.2.2 Incident Cases of TNBC 8.2.3 Gene Mutation-specific Incident Cases of TNBC 8.2.4 Stage-specific Incident Cases of TNBC 8.2.5 Age-specific Incident Cases of TNBC 8.3 Total Incident Cases of Breast Cancer in the 7MM 8.4 Total Incident Cases of TNBC in the 7MM 8.5 The United States 8.6 EU4 and the UK 8.7 Japan 9 Patient Journey 10 Marketed Therapies 10.1 Key Cross Competition 10.2 KEYTRUDA (pembrolizumab): Merck 10.2.1 Product Description 10.2.2 Regulatory Milestone 10.2.3 Other Developmental Activities 10.2.4 Clinical Trials Information 10.2.5 Safety and Efficacy 10.3 TRODELVY (sacitzumab govitecan-hziy): Gilead Sciences 10.4 TALZENNA (talazoparib): Pfizer 10.5 LYNPARZA (olaparib): AstraZeneca/Merck 10.6 TECENTRIQ (atezolizumab): Roche/Genentech To be continued in the report… 11 Emerging Drug Profiles 11.1 Key Cross Competition of Emerging Drugs 11.2 DATROWAY (Datopotamab Deruxtecan): AstraZeneca/Daiichi Sankyo 11.2.1 Drug Description 11.2.2 Other Developmental Activities 11.2.3 Clinical Trials Information 11.2.4 Safety and Efficacy 11.2.5 Analysts' View 11.3 PADCEV (Enfortumab vedotin): Astellas Pharma/Pfizer 11.4 Tilarginine: Galera Therapeutics 11.5 BNT327/PM8002: BioNTech 11.6 IMFINZI (Durvalumab): AstraZeneca To be continued in the report… 12 TNBC: Market Analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Attribute Analysis 12.4 Key Market Forecast Assumptions 12.4.1 Cost Assumptions and Rebates 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Year and Therapy Uptake 12.5 Total Market Size of TNBC in the 7MM 12.6 Market Size of TNBC by Therapies in the 7MM 12.7 Market Size of TNBC in the United States 12.8 Market Size of TNBC in EU4 and the UK 12.9 Market Size of TNBC in Japan 13 Key Opinion Leaders' Views 14 Unmet Needs 15 SWOT Analysis 16 Market Access and Reimbursement 16.1 The United States 16.2 In EU4 and the UK 16.3 Japan 17 Acronyms and Abbreviations 18 Bibliography 19 Report Methodology Related Reports PD-L1 Inhibitors Market PD-L1 Inhibitors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-L1 inhibitors companies including EQRX, CSTONE PHARMACEUTICALS, PFIZER, NOVARTIS, ARCUS BIOSCIENCES, AGENUS, TRACON PHARMACEUTICALS, SHANGHAI HENLIUS BIOTECH, INCYTE CORPORATION, among others. PARP Inhibitors Market PARP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PARP inhibitors companies including AstraZeneca, Merck, Janssen, Pfizer, Astellas, Pharma& Schweiz, AtlasMedx, AbbVie, GlaxoSmithKline, Pfizer, BeiGene, Allarity Therapeutics, among others. Triple-Negative Breast Cancer Pipeline Triple-Negative Breast Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TNBC companies, including G1 Therapeutics, Inc., Gilead Sciences, Biotheus Inc., GlaxoSmithKline, AstraZeneca, Shanghai Jiaolian Drug Research and Development Co., Ltd, Coherent Biopharma, Daiichi Sankyo Company, Merck, SynDevRx, Inc., Treadwell Therapeutics, AstraZeneca, Novartis Pharmaceuticals, NEC Corporation, Cardiff Oncology, Ocellaris Pharma, Inc., Nuvation Bio Inc., Phoenix Molecular Designs, Pure Biologics S.A., Pure Biologics S.A., Mersana Therapeutics, Zumutor Biologics Inc., Tubulis GmbH, Hinova Pharmaceuticals, Primevax, ARCE Therapeutics, HC Biopharma, Casinvent, among others. Breast Cancer Market Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key breast cancer companies including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur [email protected] + Logo: View original content:
Malaysian Reserve
2 days ago
- Malaysian Reserve
Pad-Mounted Switchgear Market worth $7.97 billion by 2030
DELRAY BEACH, Fla., July 29, 2025 /PRNewswire/ — The global Pad-Mounted Switchgear Market is anticipated to grow from estimated USD 6.13 billion in 2025 to USD 7.97 billion by 2030, at a CAGR of 5.4% during the forecast period. The global Pad-Mounted Switchgear Market is expected to grow steadily from 2025 to 2030, driven by the increasing shift toward underground power distribution systems, urban infrastructure expansion, and the upgrading of aging grid networks. As urbanization accelerates and power demands rise in both developed and developing countries, utilities and municipalities are investing in compact, safe, and reliable distribution solutions to ensure continuous power supply. Pad-mounted switchgear is crucial for maintaining electrical safety, operational continuity, and system automation across residential, commercial, and industrial settings. The shift to clean energy, the electrification of public infrastructure, and the rising use of distributed energy resources like rooftop solar and EV charging stations underscore the growing need for intelligent, automation-ready switchgear systems. Additionally, the demand for discreet, weatherproof, and tamper-resistant equipment in densely populated areas is increasing the adoption of pad-mounted switchgear. Digital advancements such as SCADA compatibility, condition monitoring, and arc-resistant designs are turning these systems into smart, modular solutions that meet the demands of modern grids. As utilities strive for greater resilience and fewer outages, especially in disaster-prone or densely populated urban areas, pad-mounted switchgear is becoming a foundational technology in the global power distribution network. Browse in-depth TOC on 'Pad-Mounted Switchgear Market' 160 – Tables60 – Figures 220 – Pages Download PDF Brochure: The industrial segment is expected to be the largest application in the Pad-Mounted Switchgear Market. The industrial segment is expected to be the largest application area in the global Pad-Mounted Switchgear Market because of the increasing need for highly reliable and continuous power in critical manufacturing and processing operations. Industries such as oil & gas, chemicals, mining, steel, cement, and automotive rely on robust electrical infrastructure to keep operations running smoothly, prevent costly downtime, and uphold safety standards. Pad-mounted switchgear systems are commonly used in these industrial facilities as they provide compact, tamper-proof, and weather-resistant enclosures suitable for tough environments. These systems enable safe power distribution, fault isolation, and quick service restoration, which are vital for operations that handle high-voltage loads and are often situated in remote or hazardous locations. Moreover, the growing automation of industrial processes and the expansion of industrial zones in emerging economies further boost the demand for advanced and smart pad-mounted switchgear solutions. Their ability to integrate with SCADA systems for real-time monitoring and control also improves operational efficiency, making them a preferred choice for modern industrial power networks. IEC standards are considered to be the largest market for pad-mounted switchgear. IEC standards are considered the largest market segment for pad-mounted switchgear due to their widespread adoption across different regions, especially in Europe, Asia Pacific, the Middle East, and Africa. The International Electrotechnical Commission (IEC) offers a globally recognized framework for designing, testing, and certifying electrical equipment, including pad-mounted switchgear, ensuring safety, reliability, and compatibility across international markets. IEC-compliant switchgear is widely used in utility, industrial, and commercial sectors where compliance with international standards is vital for equipment approvals, bid eligibility, and long-term grid integration. As many countries develop their power infrastructure and procurement policies aligning with global norms, IEC-based products provide manufacturers with scalability and standardized manufacturing processes. The IEC 62271 series, in particular, governs high-voltage switchgear and control gear, guaranteeing performance under various electrical and environmental conditions. Additionally, as modernization efforts accelerate in emerging economies, the demand for IEC-certified pad-mounted switchgear is increasing due to its durable design, suitability for underground distribution systems, and proven performance in both rural and urban settings. This global relevance, combined with rising cross-border infrastructure investments, makes IEC-standard products the dominant choice in the Pad-Mounted Switchgear Market. Europe is likely to emerge as the largest Pad-Mounted Switchgear Market Europe is set to become the largest market for pad-mounted switchgear, fueled by widespread grid modernization efforts, strict regulatory standards, and a strong push toward underground power distribution infrastructure. Many European countries are transitioning from overhead lines to underground systems to improve grid appearance, increase reliability, and guard against environmental disruptions like storms and wildfires. The European Union's ambitious goals for carbon neutrality and energy efficiency, along with directives encouraging the adoption of smart grids and renewable energy, have further boosted demand for advanced distribution technologies such as pad-mounted switchgear. Utilities across the region are increasingly investing in resilient and modular switchgear solutions that support automation, fault detection, and real-time monitoring—key needs for managing expanding decentralized energy networks. Additionally, Europe's dense urban areas and the demand for space-efficient, low-maintenance equipment make pad-mounted switchgear an ideal choice for residential, commercial, and industrial power distribution. With growing investments in green energy corridors, electric vehicle infrastructure, and digital substations, Europe is well-positioned to lead the global Pad-Mounted Switchgear Market during the upcoming years. Key Market Players The key players in this market include Eaton (Ireland), Hubbell (US), ABB (Switzerland), G&W Electric (US), S&C Electric (US), Powell (US), Federal Pacific (US), Entec Electric & Electronic (South Korea), NOJA Power (Australia), TIEPCO (Saudi Arabia), Ghorit Electricals (China), Ningbo Tianan Group (China), Trayer Switchgear (US), KDM Steel (China), Switchgear Power Systems (US), Park Detroit and Park Electric (US), Beijing Kylin Power & Technology (China), Telawne Power Equipments Pvt. Ltd. (India), Ormazabal (Brazil), and Actom (Boksburg). Request Sample Pages: Eaton (Ireland) Eaton (Ireland) is a leading player in the global Pad-Mounted Switchgear Market, known for its innovative, sustainable, and reliable distribution solutions tailored for utility, industrial, and commercial applications. The company offers a comprehensive portfolio of air-insulated, solid dielectric, and SF6-free pad-mounted switchgear designed for underground distribution systems where safety, environmental compliance, and aesthetics are critical. Eaton's switchgear is widely used in grid modernization, electric vehicle (EV) infrastructure, renewable energy zones, and critical facilities like data centers and hospitals. The company integrates advanced automation features into its systems, including remote monitoring, fault location, and FLISR capabilities, enabling utilities to develop self-healing and intelligent distribution networks. Eaton continues to expand its global presence through strategic acquisitions—such as the 50% stake in Jiangsu Huineng Electric Co., Ltd. in China—and collaborations with government and private entities, particularly in the U.S., to improve grid resilience and electrification. With its focus on digital power management, low-carbon technologies, and smart grid integration, Eaton remains a dominant force shaping the next generation of pad-mounted switchgear solutions worldwide. ABB (Switzerland) ABB (Switzerland) is a major global leader in the Pad-Mounted Switchgear Market, offering a wide range of durable, compact, and environmentally friendly solutions designed for medium-voltage underground distribution systems. Utilizing its extensive expertise in power technologies and automation, ABB delivers pad-mounted switchgear built for dependability, safety, and easy integration into smart grids. Its product lineup includes air-insulated, gas-insulated (including SF6-free options), and solid dielectric switchgear, all featuring intelligent controls, sensors, and communication interfaces for remote operation and diagnostics. ABB's pad-mounted switchgear is extensively used by utilities, renewable energy providers, transportation sectors, industrial parks, and critical infrastructure, helping clients improve network efficiency and minimize outage durations. The company places a strong emphasis on digitalization and grid automation, aligning its switchgear products with Industry 4.0 trends and energy transition efforts. ABB has invested heavily in R&D to develop eco-friendly, compact switchgear solutions that meet evolving global standards for emissions and safety. With a robust manufacturing and service presence across key regions, ABB remains a preferred supplier for large-scale grid modernization, urban infrastructure enhancements, and renewable energy projects. For more information, Inquire Now! Related Reports: Switchgear Market Gas Insulated Switchgear Market Get access to the latest updates on Pad-mounted Switchgear Companies and Pad-mounted Switchgear Industry About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content:
